Home LiteratureArticle Details
PMID: 17245336 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels.

British journal of cancer ·Vol. 96 ·No. 3 ·2007-02-12 ·Pages 445-9

Smalley KS, Contractor R, Haass NK, Lee JT, Nathanson KL, Medina CA, Flaherty KT, Herlyn M

Abstract

The loss of tumour phospho-extracellular responsive kinase (pERK) positivity is the major treatment biomarker for mitogen-activated protein kinase/extracellular responsive kinase (MEK) inhibitors. Here, we demonstrate that there is a poor correlation between pERK inhibition and the anti-proliferative effects of MEK inhibitors in melanoma cells. We suggest that Ki67 is a better biomarker for future clinical studies.

MeSH Terms
Biomarkers, Tumor/analysis Butadienes/analysis Cell Line, Tumor Cell Proliferation Extracellular Signal-Regulated MAP Kinases/analysis,antagonists & inhibitors G1 Phase Humans Ki-67 Antigen/analysis Melanoma/drug therapy,pathology Mitogen-Activated Protein Kinase Kinases/antagonists & inhibitors Mutation Nitriles/analysis Phosphoinositide-3 Kinase Inhibitors Phosphorylation Proto-Oncogene Proteins B-raf/genetics
Chemicals
Biomarkers, Tumor Butadienes Ki-67 Antigen Nitriles Phosphoinositide-3 Kinase Inhibitors U 0126 BRAF protein, human Proto-Oncogene Proteins B-raf Extracellular Signal-Regulated MAP Kinases Mitogen-Activated Protein Kinase Kinases
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Smalley K S M
The Wistar Institute, 3601 Spruce Street, Philadelphia, Pennsylvania, 19104, USA. ksmalley@wistar.org
Contractor R
Haass N K
Lee J T
Nathanson K L
Medina C A
Flaherty K T
Herlyn M
References (11)
11 references, click to expand
  1. A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?
    Int J Cancer. 2003 May 1;104(5):527-32 PMID: 12594806
  2. Suppression of BRAF(V599E) in human melanoma abrogates transformation.
    Cancer Res. 2003 Sep 1;63(17):5198-202 PMID: 14500344
  3. B-RAF is a therapeutic target in melanoma.
    Oncogene. 2004 Aug 19;23(37):6292-8 PMID: 15208680
  4. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.
    J Clin Oncol. 2004 Nov 15;22(22):4456-62 PMID: 15483017
  5. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors.
    Cancer Res. 2005 Mar 15;65(6):2412-21 PMID: 15781657
  6. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature.
    Pigment Cell Res. 2006 Aug;19(4):290-302 PMID: 16827748
  7. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.
    J Clin Oncol. 2005 Aug 10;23(23):5281-93 PMID: 16009947
  8. Distinct sets of genetic alterations in melanoma.
    N Engl J Med. 2005 Nov 17;353(20):2135-47 PMID: 16291983
  9. Amplification of CDK4 and MDM2 in malignant melanoma.
    Genes Chromosomes Cancer. 2006 May;45(5):447-54 PMID: 16419059
  10. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases.
    Mol Cancer Ther. 2006 May;5(5):1136-44 PMID: 16731745
  11. Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion.
    Am J Pathol. 2005 May;166(5):1541-54 PMID: 15855653
Article Info
Journal
British journal of cancer
Abbr.
Br J Cancer
ISSN
0007-0920
DOI
10.1038/sj.bjc.6603596
Email
ksmalley@wistar.org
Published
2007-02-12
Epub
2007-00-23
Pages
445-9
Language
English
Region
England
NLM ID
0370635
PMCID
PMC2360037
Subset
IM
Grants
NCI NIH HHS · CA 098101 · United States
NIGMS NIH HHS · GM071695 · United States
NCI NIH HHS · P01 CA025874 · United States
NCI NIH HHS · P50 CA093372 · United States
NCI NIH HHS · P30 CA010815 · United States
NCI NIH HHS · R01 CA076674 · United States
NCI NIH HHS · R01 CA080999 · United States
NCI NIH HHS · CA 47159 · United States
NCI NIH HHS · CA 80999 · United States
NCI NIH HHS · CA 93372 · United States
NCI NIH HHS · CA 76674 · United States
NCI NIH HHS · CA 10815 · United States
NCI NIH HHS · P01 CA098101 · United States
NIGMS NIH HHS · R01 GM071695 · United States
NCI NIH HHS · CA 25874 · United States
NCI NIH HHS · R01 CA047159 · United States
External Links
PubMed source DOI: 10.1038/sj.bjc.6603596 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2